Abbott said to agree to buy Alere at lower price
[BEIJING] Abbott Laboratories has agreed to buy Alere Inc at a lower price than previously offered, closing a legal battle over the merger between the two health companies, the Financial Times reported, citing unidentified people close to the matter.
Abbott agreed to buy Alere at US$51 per share rather than the previous offer of US$56, the FT reported Friday. Abbott had sued to break up its earlier $5.8 billion takeover of medical-device maker Alere, arguing the deal target hid material information about legal and regulatory problems.
The transaction has been dragging on for more than a year as Alere disclosed subpoenas on bribery investigations, restated earnings and recalled products - escalating to the Abbott suit in December.
The new agreement, valuing Alere's equity at US$4.4 billion, was expected to be announced imminently, the FT reported.
Calls to both companies outside of regular business hours went unanswered.
The offer is 21 per cent more than Alere's closing share price Thursday of US$42.31. Abbott shares ended Thursday at US$42.67. Markets in the US are closed for the Good Friday holiday.
BLOOMBERG
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Gazelle Ventures makes cash offer for No Signboard shares at S$0.0021 apiece
P&G raises annual core profit forecast on resilient demand, price hikes
Cordlife calls for trading halt after shares sink to all-time low, pending announcement
Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom
Swiss watch exports plunge as China and Hong Kong demand dries up
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO